Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a.

Journal of neurology·2023
Same author

Fully Automatic Method for Reliable Spinal Cord Compartment Segmentation in Multiple Sclerosis.

AJNR. American journal of neuroradiology·2023
Same author

Prognostic biomarkers in primary progressive multiple sclerosis: Validating and scrutinizing multimodal evoked potentials.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2022
Same author

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2020
Same author

Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment.

European journal of neurology·2020
Same author

Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods.

European radiology·2019

Related Experiment Video

Updated: Jul 15, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Pooled historical MRI data as a basis for research in multiple sclerosis--a statistical evaluation.

S Schach1, M Scholz, J S Wolinsky

  • 1Department of Statistics, Dortmund University, D-44221 Dortmund, Germany.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|April 28, 2007
PubMed
Summary

Pooled placebo data can serve as historical controls in therapeutic studies. However, significant heterogeneity exists in magnetic resonance imaging (MRI) measures, even after adjustments, requiring careful statistical consideration.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Related Experiment Videos

Last Updated: Jul 15, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Area of Science:

  • Neuroimaging
  • Clinical Trials
  • Biostatistics

Background:

  • Pooled placebo data are valuable for historical controls and power calculations in therapeutic studies.
  • Investigating heterogeneity in placebo arm data is crucial for assessing database utility.
  • The Sylvia Lawry Centre for Multiple Sclerosis Research maintains a database of controlled studies.

Purpose of the Study:

  • To assess the usefulness of pooled placebo arm data from multiple sclerosis (MS) trials as historical controls.
  • To investigate the degree of heterogeneity in magnetic resonance imaging (MRI) measures within the pooled placebo data.
  • To determine if adjustments for population differences can mitigate heterogeneity.

Main Methods:

  • Analysis of pooled placebo arm data from 14 controlled studies.
  • Adjustment of magnetic resonance imaging (MRI) measures for differences in study populations.
  • Stratification analysis to account for heterogeneity.

Main Results:

  • Significant heterogeneity was observed in MRI measures across pooled placebo groups, even after population adjustments.
  • Heterogeneity was substantially reduced when comparing studies from the same image analysis center.
  • The pooled database remains useful for analyzing inter-variable relationships when heterogeneity is explicitly managed.

Conclusions:

  • Pooled placebo data offer utility for statistical analyses but require careful handling due to inherent heterogeneity.
  • Explicitly accounting for heterogeneity as a stratification factor is essential for valid comparisons.
  • Comparing new treatment groups with pooled data necessitates caution due to potential variations in MRI measures.